亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯(lián)系方式|購物車
企業(yè)會員第1年

浙江臺州市保隆化工有限公司  

抗腫瘤產(chǎn)品,醋酸格拉替雷

搜索
新聞中心
  • 暫無新聞
產(chǎn)品分類
  • 暫無分類
聯(lián)系方式
  • 聯(lián)系人:董女士
  • 電話:86-0576-88702852
  • 郵件:eric@bolonpharm.com
站內(nèi)搜索
 
榮譽資質(zhì)
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產(chǎn)品 > 瑞替加濱150812-13-8
瑞替加濱150812-13-8
單價 面議對比
詢價 暫無
發(fā)貨 浙江付款后3天內(nèi)
過期 長期有效
更新 2014-03-12 14:28
 
詳細信息

中文名稱:

瑞替加濱

中文同義詞:

N-(2-氨基-4-(4-氟芐氨基)苯基)氨基甲酸乙酯****;瑞替加濱****;瑞替加濱***;瑞替加賓

英文名稱:

Retigabine Dihydrochloride

英文同義詞:

D 20443;Ethyl [2-amino-4-[[(4-fluorophenyl)methyl]amino]phenyl]carbamate Dihydrochloride;N-(2-Amino-4-(4-fluorobenzylamino)phenyl)carbamic Acid Ethyl Ester Dihydrochloride;Retigabine Dihydrochloride;Retigabine 2HCL;Retigabine HCl;D 20443 dihydrochloride;D20443 dihydrochloride

CAS:

150812-13-8

分子式:

C16H20Cl2FN3O2

分子量:

339.79

EINECS:

 

Mol文件:

150812-13-8.mol

©2025 浙江臺州市保隆化工有限公司 版權所有   技術支持:化工網(wǎng)   訪問量:4592  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |